Miza III closes qualifying transaction with SciSparc

Executive Summary

• Neurothera Labs Inc. (formerly Miza III Ventures Inc.) completed an arm‑length share sale with SciSparc Ltd., resulting in a name change, new ticker (NTLX), and issuance of 63.3 M common shares, 4 M warrants, 48 M contingent rights, and a 3 M‑share finder’s fee.
• The transaction includes payment warrants at $0.25 per share (exercisable through 2030) and three tiers of contingent rights tied to uplisting, $10 M financing, or clinical trial completion by 2029.
• Approximately 64.1 M shares, 4 M warrants, and 48 M contingent rights are placed in escrow with staged release provisions; trading under NTLX is expected around Oct 27 2025.

Key Details

• Transaction Parties: Neurothera Labs Inc. (buyer) and SciSparc Ltd. (seller).
• Effective Date: Oct 22 2025 (closing); name change to Neurothera Labs Inc. and ticker NTLX effective same date.
• Consideration Issued to SciSparc:
• 63.3 M common shares of Neurothera.
• 4 M common share purchase warrants (exercise price $0.25 per share, exercisable until Oct 22 2030).
• 48 M contingent rights (16 M shares each upon:
  1. Uplisting to NYSE or Nasdaq by Oct 22 2027;
  2. Raising ≥ US$10 M in equity/debt financing by Oct 22 2029;
  3. Completion of a clinical trial by Oct 22 2029).
• Finder’s Fee: 3 M common shares issued to designated parties.
• Statutory Hold Period: All securities issued (target shares, warrants, contingent rights, finder’s shares) subject to hold until Feb 23 2026.
• Escrow Arrangements:
• Principals holding 64,052,000 common shares, 4 M warrants, and 48 M contingent rights placed in escrow with Endeavor Trust Corp.; 10% released at final exchange bulletin, then 15% each six‑month anniversary.
• Additional shareholders subject to prior escrow (3 M shares + 500k ISOs); 25% released at final bulletin, then 25% each six‑month anniversary.
• Trading Resumption: Anticipated on TSX Venture Exchange under ticker NTLX on or about Oct 27 2025.
• Board & Management Post‑Closing:
• Oz Adler – CEO
• Gabriel Kabazo – CFO & Corporate Secretary
• Adi Zuloff‑Shani – CTO
• Directors: Itschak Shrem, Lior Vider (Audit Chair), Alon Dayan (Audit Member), Ohad David (Audit Member)
• Auditor Appointment: Planned appointment of Brightman Almagor Zohar & Co. (Deloitte Global Network).
• Fiscal Year‑End Change: New fiscal year‑end set to Dec 31; interim financials for nine months ended Sept 30 2025 to be filed within 60 days of period end.

Notable Quotes

(No direct quotes provided in the release.)